[Image from Jp Valery on Unsplash]
Across 2021, medtech has seen a wide range of mergers and acquisitions covering several areas of devices, pharmaceuticals and more.Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.
Here are the 10 biggest mergers and acquisitions in medtech in 2021:
Next>>
The medtech industry hit a slight lull in the early stages of 2021 and, after signs of a rebound, it has soared beyond levels ever before seen.
MassDevice‘s MedTech 100 Index had been building up steam in the month of April, rising from 102.16 points at the beginning of March all the way to 109.39 to end the week before last (April 9). Having only set its previous all-time best of 110.96 on Feb. 15, the industry’s topsy-turvy run gave no indication of which direction it was heading next.
However, after the rise over the past couple of weeks, the industry rode that wave to a new all-time high of 112.25 to end last week on April 16. That represents a 2.6% rise from the previous week’s tally.
Improvements continue to shine a light on the strong position the industry has settled into a year on from the height of the COVID-19 pandemic’s impact on medtech, as the industry has produced an 21.6% rise from the pre-pandemic high of 92.32 (set on Feb. 1…
DiaSorin announced that it agreed to acquire Luminex in an all-cash transaction worth approximately $1.8 billion.
Saluggia, Italy-based DiaSorin’s purchase at $37 per share of Luminex represents a 23.1% premium to Luminex shareholders based on the unaffected closing stock price of the company on Feb. 24, 2021, which was the date prior to press rumors regarding a potential sale, according to a news release. The transaction is expected to close in the third quarter of this year, subject to Luminex shareholder approval.
Luminex develops diagnostic testing products, including platforms based on multiplexing technology. The Austin, Texas-based company’s diagnostics include COVID-19 tests, which received FDA emergency use authorization last year.
DiaSorin, a diagnostics company itself, said in the release that the purchase will broaden its positioning in the molecular diagnostics space while strengthening its existing value proposition in line with…
Luminex (NSDQ:LMNX) announced today that it received FDA emergency use authorization (EUA) for its xMAP SARS-CoV-2 multi-antigen IgG assay for COVID-19.
Austin, Texas-based Luminex said in a news release that its serology assay can identify the presence of antibodies in those who have been infected with the SARS-CoV-2 virus causing COVID-19. The newly authorized assay can run on any of Luminex’s xMAP-based, high-throughput multiplex platforms, including MAGPIX, the Luminex 200, and FLEXMAP 3D.
The company’s xMAP assay delivers results for up to 96 patient samples in under three hours, detecting antibodies of the IgG antibodies at a specificity of 100% in human serum and more than 99% in human plasma, according to results from clinical studies.
“More than 17,000 xMAP systems have been sold to laboratories around the world, and this FDA authorization creates important new opportunities for these labs to rapidly expand their COVID-19 testi…